


International Task Force for Prevention of Coronary Heart Disease

2003 Consensus on the management of dyslipidemias

Symposium of the International Task Force for Prevention of Coronary Heart Disease

April 26th, 2003

Pasteur Institute, Paris



www.chd-taskforce.com



www.pasteur.fr






program

Session I		Chairmen: Gerd Assmann, Tony Gotto
09.00 - 09.20	Jean-Charles Fruchart	Molecular mechanisms of statins and PPAR- α agonists: recent findings
09.20 - 09.40	Peter Libby	Statins and PPAR- α agonists: arterial wall and vascular interaction
09.40 - 10.00	Gerd Assmann	Patients at risk for myocardial infarction and stroke
10.00 - 10.20	Rory Collins	Statins: the HPS experience
10.20 - 10.40		Discussion
10.40 - 11.00		Coffee break

Session II		Chairmen: Eric Bruckert, Rodolfo Paoletti
11.00 - 11.20	Pierre Amarencu	Statins, PPAR- α agonists, and stroke
11.20 - 11.40	Alfredo Postiglione	Statins, farnesyl transferase inhibition and stroke protection
11.40 - 12.00	Michel Farnier	Combination therapy for aggressive lipid lowering
12.00 - 12.20	Andrew Neil	Combination therapy: Statins and fibrates
12.20 - 12.40		Discussion
12.40 - 13.40		break

Session III		Chairmen: Bryan Brewer, Jean-Charles Fruchart
13.40 - 14.00	Jean-Marc Lablanche	Statins in the acute coronary syndrome
14.00 - 14.20	Jean Davignon	The cardioprotective effects of statins
14.20 - 14.40	Tatsuhiko Kodama	DNA microarrays to detect pleiotropic effects of statins
14.40 - 15.00	Arnold von Eckardstein	Statins, PPAR- α agonists, and HDL
15.00 - 15.20		Discussion
15.20 - 15.40		Coffee break



Session IV		Chairmen: Alberico Catapano, Jean Davignon
15.40 - 16.00	Matti Tikkanen	Statin treatment in women
16.00 - 16.20	Yasushi Saito	Improvement of dyslipidemia depends on the reduction of visceral fat accumulation
16.20 - 16.40	Tohru Funahashi	Adiponectin and the metabolic syndrome
16.40 - 17.00	Karl Lauterbach	Cost-effectiveness of statins
17.00 - 17.20		Discussion / End